PATENT
ATTORNEY DOCKET NO. 00108/017004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Stuart A. Lipton
Serial No.: 08/346,910
Filed : November 30, 1994
Title : PROTEIN 68075 AND ITS USE FOR REGENERATING NERVE CELL PROCESSES

Art Unit: 1812
Examiner: S. Cermak

Commissioner of Patents and Trademarks
Washington, DC 20231

DECLARATION OF DR. DANA LEIFER UNDER 37 CFR §1.132

I, DANA LEIFER, declare:

1. I am currently an assistant professor at Yale University School of Medicine in the Department of Neurology. From July 1989 to August 1993, I was in the Department of Neurology at Harvard Medical School, first as an Instructor of Neurology and later as an Assistant Professor of Neurology. During that time, I worked in the laboratory of Dr. Stuart Lipton and performed experiments using clone TR2B, now also known as ATCC accession number 75949, as I understand it.

2. I personally received the cDNA clone known as TR2B, sent by Dr. Rachael Neve on May 12, 1990, as well as four other samples of cDNA isolated from the same fetal human brain library using the same probe (which I understand is now ATCC accession number 68075). The four other clones were called TR5B, TR6B, TR11A, and TR12B, and all clones were in the bacteriophage vector λgt11. I subcloned clone TR2B from its lambda vector into a plasmid vector, pBluescript, using the restriction endonuclease

Date of Deposit March 20, 1995
I hereby certify under 37 CFR 1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231.
Kathleen M. O'Shea
Kathleen M. O'Shea

EcoRI on June 20, 1990. On July 11, 1990, I made a maxiprep of the subcloned TR2B in order to have an amplified stock supply for further experiments. This supply was stored in TE at 4°C. Shortly thereafter, I made a glycerol stock of the subcloned TR2B. Both stocks were stored in the laboratory of Dr. Stuart Lipton. Since the stocks were made, portions have been periodically removed by me or personnel under my supervision in order to conduct ongoing research involving this clone.

4. In August 1993, I accepted my current position at Yale University and moved my laboratory there. The glycerol stock of clone TR2B was moved in a cooler with dry ice, and the amplified stock was moved in a cooler on ice, by personnel from a moving van company. Since then, these stocks have been stored in my laboratory at Yale under restricted access. A quantity of the original stocks still exist.

5. In November 1994, I sent a sample of original TR2B stock to Dr. Dimitri Krainc for the purposes of amplifying it to make an ATCC deposit.

6. I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may

jeopardize the validity of the application or any patents issued thereon.

Date: 3/10/95

Dana Leifer, M.D.

83903.B11